Additionally, we also recommend further analysis in terms of in vitro assays to validate the results from this in silico study on growth and viability changes in the presence of these drugs and whether there are genes, gene products, and or enzymes that could potentially upregulate STEAP2 in its signaling pathway leading to its role in the development and progression of prostate cancer. This evidence concerns the gene STEAP2 and prostate carcinoma.